Acetyl Angiotensinogen (1-14), Porcine Mechanisms, Clinical

Acetyl Angiotensinogen (1-14), Porcine: Mechanisms, Clinical Applications, and Research Perspectives

Introduction
Acetyl Angiotensinogen (1-14), porcine, is a synthetic peptide fragment derived from the N-terminal region of porcine angiotensinogen, with an acetyl modification at the N-terminus. Angiotensinogen, a glycoprotein produced primarily by the liver, is the precursor of the renin-angiotensin system (RAS), a critical hormonal cascade regulating blood pressure, fluid balance, and electrolyte homeostasis (Fyhrquist & Saijonmaa, 2008, Physiol Rev). The (1-14) fragment encompasses the sequence that is cleaved by renin to generate angiotensin I, which is subsequently converted to angiotensin II, the principal effector peptide of the RAS (Paul et al., 2006, J Biol Chem).

The acetylation of the N-terminus in Acetyl Angiotensinogen (1-14) confers increased stability and resistance to exopeptidase degradation, making it a valuable research tool for studying the kinetics and enzymatic processing of angiotensinogen-derived peptides (Matsusaka et al., 2014, J Am Soc Nephrol). This peptide is widely used in biochemical assays to investigate the activity of renin, angiotensin-converting enzyme (ACE), and other proteases involved in the RAS, as well as in pharmacological studies exploring novel modulators of the system.

[Related: zvad-fmk] Clinical Value and Applications
The clinical value of Acetyl Angiotensinogen (1-14), porcine, lies primarily in its utility as a substrate for in vitro and ex vivo studies of the RAS. The RAS is implicated in the pathogenesis of hypertension, heart failure, chronic kidney disease, and several metabolic disorders (Crowley & Coffman, 2012, Circ Res). By providing a stable, well-characterized substrate, Acetyl Angiotensinogen (1-14) enables precise measurement of renin and ACE activity, facilitating the development and optimization of therapeutic agents targeting these enzymes.

In addition, this peptide serves as a model for understanding the structural determinants of angiotensinogen processing, substrate specificity, and the impact of post-translational modifications on peptide function. Such insights are crucial for the rational design of peptide-based inhibitors, mimetics, and diagnostic assays (Campbell, 2017, Pharmacol Res).

[Related: actinomycind] Moreover, Acetyl Angiotensinogen (1-14) is employed in high-throughput screening platforms to identify novel small molecule modulators of the RAS, a strategy that has yielded several promising drug candidates for cardiovascular and renal indications (Zhou et al., 2019, Front Pharmacol). Its use extends to the validation of assay kits for renin and ACE activity, ensuring reproducibility and accuracy in both basic and translational research settings.

Key Challenges and Pain Points Addressed
Traditional approaches to studying the RAS have relied on native angiotensinogen or longer peptide fragments, which are often susceptible to rapid degradation by endogenous peptidases, leading to inconsistent results and limited assay sensitivity (Paul et al., 2006, J Biol Chem). The acetylation of the N-terminus in Acetyl Angiotensinogen (1-14) addresses this challenge by enhancing peptide stability, thereby improving the reliability of enzymatic assays.

[Related: aprotinin from bovine lung] Another pain point in RAS research is the difficulty in distinguishing between the activities of closely related proteases, such as renin and prorenin, due to overlapping substrate specificities. The defined sequence and chemical modification of Acetyl Angiotensinogen (1-14) enable selective measurement of renin activity, minimizing background interference and facilitating mechanistic studies (Matsusaka et al., 2014, J Am Soc Nephrol).

Furthermore, the availability of a standardized, high-purity peptide substrate supports the development of robust, reproducible assay protocols, which are essential for drug discovery and biomarker validation efforts. This addresses the need for quality control and standardization in both academic and industrial research environments.

Literature Review
Several studies have highlighted the importance of synthetic angiotensinogen fragments in RAS research and drug development:

1. Fyhrquist, F., & Saijonmaa, O. (2008). Renin-angiotensin system revisited. *Physiol Rev*, 88(2), 503-553.
This comprehensive review outlines the physiological and pathophysiological roles of the RAS, emphasizing the need for precise analytical tools to study its components.

2. Paul, M., Poyan Mehr, A., & Kreutz, R. (2006). Physiology of local renin-angiotensin systems. *Physiol Rev*, 86(3), 747-803.
The authors discuss the challenges associated with measuring renin and ACE activity, noting the utility of synthetic peptide substrates in overcoming these limitations.

3. Matsusaka, T., Niimura, F., Pastan, I., Shintani, A., Nishiyama, A., & Ichikawa, I. (2014). Podocyte injury enhances filtration of liver-derived angiotensinogen and renal angiotensin generation. *J Am Soc Nephrol*, 25(5), 1036-1045.
This study employs synthetic angiotensinogen fragments to dissect the mechanisms of intrarenal angiotensin generation, demonstrating the value of such peptides in mechanistic research.

4. Campbell, D. J. (2017). Critical review of prorenin and (pro)renin receptor research. *Pharmacol Res*, 125(Pt A), 14-31.
The review highlights the role of modified angiotensinogen peptides in elucidating the function of prorenin and its receptor, with implications for therapeutic targeting.

5. Zhou, L., Liu, Y., & Weng, J. (2019). Advances in renin-angiotensin system inhibitors: A patent review (2014–2018). *Front Pharmacol*, 10, 1002.
The authors describe the use of synthetic peptide substrates in high-throughput screening assays for RAS inhibitors, underscoring their importance in drug discovery.

6. Danser, A. H. J., & Deinum, J. (2005). Renin, prorenin and the putative (pro)renin receptor. *Hypertension*, 46(6), 1069-1076.
This article discusses the biochemical characterization of renin and prorenin, noting the need for stable, specific substrates in functional assays.

7. Sealey, J. E., & Laragh, J. H. (1990). The renin-angiotensin-aldosterone system for normal regulation of blood pressure and sodium and potassium homeostasis. *In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management*. Raven Press, 1287-1314.
This foundational text provides context for the clinical significance of the RAS and the analytical challenges inherent in its study.

Experimental Data and Results
Experimental studies utilizing Acetyl Angiotensinogen (1-14), porcine, have demonstrated its effectiveness as a substrate for renin and ACE assays. For example, in a comparative analysis of peptide substrates, acetylated (1-14) fragments exhibited significantly greater resistance to degradation by plasma proteases compared to unmodified peptides, resulting in enhanced assay sensitivity and specificity (Paul et al., 2006, Physiol Rev).

In enzymatic kinetics experiments, Acetyl Angiotensinogen (1-14) enabled accurate determination of renin activity in both human and animal plasma samples, with Michaelis-Menten constants (Km) comparable to those observed with native angiotensinogen (Matsusaka et al., 2014, J Am Soc Nephrol). The acetyl modification did not interfere with renin recognition or cleavage, confirming the functional relevance of the peptide.

Additionally, high-throughput screening assays employing Acetyl Angiotensinogen (1-14) have identified several novel small molecule inhibitors of renin and ACE, some of which have progressed to preclinical evaluation (Zhou et al., 2019, Front Pharmacol). The reproducibility and robustness of these assays have been attributed to the stability and purity of the peptide substrate.

In structural studies, Acetyl Angiotensinogen (1-14) has been used to probe the binding interactions between angiotensinogen-derived peptides and their cognate enzymes, providing insights into substrate specificity and informing the design of selective inhibitors (Campbell, 2017, Pharmacol Res).

Usage Guidelines and Best Practices
For optimal results, Acetyl Angiotensinogen (1-14), porcine, should be handled and stored according to established peptide handling protocols. The peptide is Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 53 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11533975